Shifamed‘s Adona Medical announced today that it completed enrollment in the ATHENS-HF first-in-human study of its interatrial shunt. The company initiated the study last year, announcing the successful first-in-human use of the novel shunt in patients with heart failure in October. Adona Medical utilizes nitinol’s shape memory properties in an adjustable, bi-atrial-sensing heart device. The device […]
Adona Medical
How to design medtech clinical trials that deliver
Transparent, well-designed clinical trials are a must. Here’s advice on how to get there. Scott Nelson, co-founder and CEO of FastWave Medical Dozens of medical devices annually make it onto the FDA’s list of the newest approved medtech. Yet, alongside this progress, the agency faces a stark reality: over the last decade, faulty devices have been […]
Shifamed’s Adona Medical raises $33.5M
Shifamed portfolio company Adona Medical announced today that it raised $33.5 million in a Series C financing round to support its adjustable heart shunt technology. Cormorant Asset Management and TCP Health Ventures led the financing. Excelstar Ventures, the PA MedTech VC Fund II, Unorthodox Ventures, AMED Ventures and other new and existing investors participated. (Our sibling site […]
Shifamed’s Adona Medical unveils next-gen heart failure management platform
Shifamed portfolio company Adona Medical today announced the introduction of its next-generation heart failure platform. Brian Fahey, Adona Medical co-founder and CEO, unveiled the developing interatrial shunt technology in a presentation at the CSI Frankfurt 2023 conference. The Adona heart failure management platform features an adjustable interatrial shunt with integrated bi-atrial pressure monitoring. Its shunt […]
Adona Medical raises $20.5M
Shifamed portfolio company Adona Medical filed an SEC Form D to confirm the sale of nearly $20.5 million in equity. Campbell, Calif.-based Adona Medical is offering more than $24.8 million in equity in a new notice that had its first sale on Aug. 20, 2020. Adona Medical does not intend for the offering to last […]
